The effects and side effects of trifluridine and tipiracil (Lansifer)

Trifluridine and tipiracil (Lonsurf/Lonsurf), as a powerful anti-cancer drug, play an important role in the treatment of certain types of digestive system malignancies such as colon cancer, rectal cancer, and gastric cancer. It can be used alone or in combination with bevacizumab, providing a new treatment option for patients who have already received other chemotherapy or are unable to tolerate other chemotherapy regimens.

Trifluridine is a thymidine analogue drug that inhibits cancer cells by interfering with the growth mechanism of cancer cells. Tipiracil, as a thymidine phosphorylase inhibitor, enhances the effectiveness of the drug by slowing down the body's breakdown of trifluridine. However, although trifluridine and tipiracil have shown good efficacy in treating cancer, patients may also experience some adverse effects during treatment.

The most common adverse reactions (including laboratory abnormalities) with trifluridine and tipiracil monotherapy are neutropenia, anemia, thrombocytopenia, fatigue, nausea, decreased appetite, diarrhea, vomiting, abdominal pain, and pyrexia. The most common adverse reactions (including laboratory abnormalities) of trifluridine tipiracil combined with bevacizumab are neutropenia, anemia, thrombocytopenia, fatigue, nausea, increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), increased alkaline phosphatase, decreased sodium, diarrhea, abdominal pain, and decreased appetite.

In summary, trifluridine and tipiracil are of great value in the treatment of malignant tumors of the digestive system, but patients may experience a variety of adverse reactions during use. Therefore, when using this drug, doctors need to fully understand its adverse reaction spectrum and develop a personalized treatment plan based on the patient's specific situation to ensure the safety and effectiveness of the treatment.